Literature DB >> 27407569

Phacoemulsification : our experience at a large Military Hospital.

Vijay Mathur1, V K Singh2.   

Abstract

Cataract surgery by means of phacoemulsification was started at a large Military Hospital in March 2001. First 70 cases in whom phacoemulsification was performed between 15 March 2001 and 31 December 2001 were followed-up and evaluated. The surgical techniques used, complications and post-operative recovery following this new surgical technique have been discussed. Our experience of conversion from standard extracapsular cataract extraction to phacoemulsification has also been shared.

Entities:  

Keywords:  Astigmatism; Continuous Curvilinear Capsulorexhsis; Phacoemulsification; Posterior Capsular Rupture

Year:  2011        PMID: 27407569      PMCID: PMC4923430          DOI: 10.1016/S0377-1237(04)80149-7

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  4 in total

1.  Visual outcome and complications of residents learning phacoemulsification.

Authors:  R Thomas; S Naveen; A Jacob; A Braganza
Journal:  Indian J Ophthalmol       Date:  1997-12       Impact factor: 1.848

Review 2.  Physical and mechanical principles of phacoemulsification and their clinical relevance.

Authors:  L Yow; S Basti
Journal:  Indian J Ophthalmol       Date:  1997-12       Impact factor: 1.848

3.  Incidence and management of posteriorly dislocated nuclear fragments following phacoemulsification.

Authors:  A Mathai; R Thomas
Journal:  Indian J Ophthalmol       Date:  1999-09       Impact factor: 1.848

Review 4.  Towards achieving small-incision cataract surgery 99.8% of the time.

Authors:  R Thomas; T Kuriakose; R George
Journal:  Indian J Ophthalmol       Date:  2000-06       Impact factor: 1.848

  4 in total
  1 in total

1.  Causes of subnormal vision in patients following cataract surgery at a tertiary hospital in Kashmir.

Authors:  Andleeb Ahangar; Aalia Rasool Sufi; Mushood Nabi; Muddasar Hassan Rather
Journal:  Int Ophthalmol       Date:  2014-02-13       Impact factor: 2.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.